Amgen Inc.

The University of North Carolina at Chapel Hill

Angen Inc.

Michael T Brewer

Robert C Thompson

Tadahiko Kohno

Stephen P Eisenberg

Rebecca W Vanderslice

Charles C Squires

Walker H Busby, Jr

David R Clemmons

James Vannice

Michael W King

Karin K Hale

Compounds are disclosed having the general formula R -X-R , wherein R and R are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R and R may be the same or different. Preferred R and R groups are TNF inhibitors.

PEGylation reagents and compounds formed therewith

The present invention provides nucleic acid molecules encoding a 30kDa TNF inhibitor or a fragment thereof having at least one non-native cysteine residue at the N-terminus, C-terminus, residue 14, or residue 15.

Nucleic acids encoding TNF inhibitor and method of production

At least two substantially purified tumor necrosis factor (TNF) inhibitors are disclosed which are glycoproteins that are active against TNF. The isolation of 3O kDa and 40 KDa TNF inhibitor from urine is disclosed. The deglycosylated form of the 3O kDa TNF inhibitor and 40 kDa TNF inhibitor are described as being active against TNF. The 40 kDa TNF inhibitor is active against both TNF alpha a TNF beta. The amino acid sequence of the 30 kDa TNF inhibitor and the 40 kDa TNF inhibitor are disclosed. Methods for isolating the TNF inhibitors from human U937 cell medium and producing the proteins by recombinant-DNA methods are also described.

Tumor necrosis factor (TNF) inhibitor and method for obtaining the same

Insulin-like growth factor I and II binding protein have potentiating and inhibiting activities. Cloning vectors and portable DNA sequences are disclosed.

Method for potentiating and inhibiting insulin-like growth factor

Growing community of inventors

Boulder, CO, United States of America

Michael T Brewer